Holdings
Janus Henderson Global Life Sciences Fund
As of Jun 30, 2026, Janus Henderson Global Life Sciences Fund reported 82 positions worth US$5.65B. Largest: Eli Lilly and Company, Johnson & Johnson and AbbVie Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly and Company | 456K | US$546M | −43,894 | Jun 30, 2026 |
| Johnson & Johnson | 1.62M | US$412M | +71,242 | Jun 30, 2026 |
| AbbVie Inc. | 1.08M | US$271M | +109K | Jun 30, 2026 |
| UnitedHealth Group Incorporated | 634K | US$264M | +33,038 | Jun 30, 2026 |
| AstraZeneca PLC | 1.22M | US$228M | −1,967 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 937K | US$175M | −151K | Jun 30, 2026 |
| argenx SE | 165K | US$153M | new | Jun 30, 2026 |
| Novartis AG | 952K | US$149M | new | Jun 30, 2026 |
| Thermo Fisher Scientific Inc | 270K | US$135M | +4,813 | Jun 30, 2026 |
| Praxis Precision Medicines, Inc. | 379K | US$127M | −15,618 | Jun 30, 2026 |